LYEL News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

LY

Mkt Cap

$198.9M

Volume

164.35K

Next Earnings

November 11th

Loading chart

LY

LYELLyell Immunopharma, Inc. Common Stock

LYEL

Pay with—

Available Balance0.00

LY

Mkt Cap

$200.7M

Volume

164.35K

Next Earnings

November 11th

Chart Financials Earnings News About Insider Filings

Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European Hematology Association 2026 CongressLyell Immunopharma announced updated safety data for ronde-cel, its dual-targeting CD19/CD20 CAR T-cell therapy, showing no Grade ≥3 cytokine release syndrome and low Grade ≥3 neurotoxicity rates in over 100 patients with relapsed/refractory large B-cell lymphoma. Translational data revealed enhanced memory potential of CAR T cells and durable responses, particularly in patients with low antigen expression. The company expects pivotal trial data in mid-2027 with BLA submission to follow.GlobeNewswire Inc. · Jun 12, 2026

Lyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 ExpansionLyell Immunopharma announced positive safety data for LYL273, its GCC-targeted CAR T-cell therapy for metastatic colorectal cancer. Gastrointestinal prophylaxis significantly reduced Grade ≥2 diarrhea/colitis from 55% to 10%, with no Grade ≥3 cytokine release syndrome or neurotoxicity observed. The Phase 1 trial has been amended to Phase 1/2 design to enable seamless expansion into a potential pivotal Phase 2 trial, with an End-of-Phase 1 FDA meeting expected by end of 2026.GlobeNewswire Inc. · Jun 8, 2026

Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business OfficerLyell Immunopharma closed an additional $50 million tranche from its $100 million equity private placement following achievement of a clinical milestone for rondecabtagene autoleucel (ronde-cel) in its PiNACLE pivotal trial for relapsed/refractory large B-cell lymphoma. The company also appointed Smital Shah as Chief Financial and Business Officer. With this funding, Lyell expects sufficient cash runway into Q2 2027.GlobeNewswire Inc. · Mar 9, 2026

Century Therapeutics Appoints Accomplished Biotechnology Leaders Dr. Han Lee and Dr. Martin Murphy to Board of DirectorsCentury Therapeutics announced the appointments of Dr. Han Lee and Dr. Martin Murphy to its Board of Directors, bringing extensive experience in biotechnology, corporate development, and life science investment.GlobeNewswire Inc. · Dec 9, 2025

Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and ExpositionLyell Immunopharma reported promising clinical trial results for ronde-cel, a CAR T-cell therapy targeting large B-cell lymphoma, showing high response rates and a manageable safety profile across multiple treatment lines.GlobeNewswire Inc. · Dec 7, 2025

Lyell Announces Two Oral Presentations from the Phase 1/2 Clinical Trial of Ronde-Cel for the Treatment of Aggressive Large B-Cell Lymphoma at the 67th ASH Annual Meeting and ExpositionLyell Immunopharma presented clinical trial data for ronde-cel, a dual-targeting CD19/CD20 CAR T-cell therapy for aggressive large B-cell lymphoma, highlighting promising response rates and safety profile at the 67th ASH Annual Meeting.GlobeNewswire Inc. · Nov 3, 2025

Biotech Underdogs Line Up for Pivotal Shots at Game-Changing Cancer TreatmentsSeveral biotech companies are developing innovative cancer treatments, with promising clinical trial results in various cancer types, focusing on immunotherapy and personalized medicine approaches.Benzinga · Jul 29, 2025

Lyell Immunopharma to Participate in the H.C. Wainwright “HCW@Home” SeriesLyell Immunopharma announced positive clinical data for its lead product candidate LYL314, an autologous dual-targeting CD19/CD20 CAR T-cell therapy, in the treatment of relapsed and/or refractory large B-cell lymphoma. The data showed high rates of durable complete responses in patients treated in the third- or later-line setting.GlobeNewswire Inc. · Jun 23, 2025

Lyell Immunopharma Announces Oral Presentation of New Clinical Data from the Phase 1/2 Trial of LYL314 for the Treatment of Large B-cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) 2025Lyell Immunopharma announced that new clinical data from the Phase 1/2 trial of LYL314, a dual-targeting CD19/CD20 CAR T-cell product candidate, will be presented at the ICML 2025 conference. LYL314 has received Regenerative Medicine Advanced Therapy and Fast Track designations from the FDA for the treatment of relapsed and/or refractory diffuse large B-cell lymphoma.GlobeNewswire Inc. · May 1, 2025

Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its Pipeline to Focus on Next-Generation CAR T-cell TherapiesLyell Immunopharma announced the acquisition of ImmPACT Bio, a clinical-stage biotechnology company, to strengthen its pipeline of next-generation CAR T-cell therapies. Lyell will prioritize the development of ImmPACT's lead program, IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidate, and discontinue the development of some of its own programs.Benzinga · Oct 24, 2024

to start trading

LY

LYELLyell Immunopharma, Inc. Common Stock

LYEL

Pay with—

Available Balance0.00

Your PositionYou don't own any LYEL yet.

Related Tickers

Earnings